JP2020514301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514301A5 JP2020514301A5 JP2019537110A JP2019537110A JP2020514301A5 JP 2020514301 A5 JP2020514301 A5 JP 2020514301A5 JP 2019537110 A JP2019537110 A JP 2019537110A JP 2019537110 A JP2019537110 A JP 2019537110A JP 2020514301 A5 JP2020514301 A5 JP 2020514301A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- domain monomer
- monomer
- polypeptide
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000178 monomer Substances 0.000 claims 84
- 229920001184 polypeptide Polymers 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 239000000539 dimer Substances 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 230000015572 biosynthetic process Effects 0.000 claims 14
- 230000000295 complement effect Effects 0.000 claims 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443523P | 2017-01-06 | 2017-01-06 | |
| US62/443,523 | 2017-01-06 | ||
| PCT/US2018/012689 WO2018129397A1 (en) | 2017-01-06 | 2018-01-05 | Compositions and methods related to engineered fc-antigen binding domain constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514301A JP2020514301A (ja) | 2020-05-21 |
| JP2020514301A5 true JP2020514301A5 (enExample) | 2021-02-18 |
Family
ID=62791385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537110A Pending JP2020514301A (ja) | 2017-01-06 | 2018-01-05 | 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200040084A1 (enExample) |
| EP (1) | EP3565595A4 (enExample) |
| JP (1) | JP2020514301A (enExample) |
| AU (1) | AU2018205272A1 (enExample) |
| CA (1) | CA3049426A1 (enExample) |
| RU (1) | RU2019124709A (enExample) |
| WO (1) | WO2018129397A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210206857A1 (en) * | 2018-05-21 | 2021-07-08 | Bioprocessia Technologies Llc | Multivalent protein complexes |
| BR112021000392A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
| AU2019300020A1 (en) * | 2018-07-11 | 2021-02-18 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered Fc-antigen binding domain constructs |
| EP3820910A4 (en) * | 2018-07-11 | 2022-06-22 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATING TO ENGINEERED FC ANTIGEN-BINDING DOMAIN CONSTRUCTS |
| BR112021000415A2 (pt) * | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
| BR112021016829A2 (pt) | 2019-02-26 | 2021-10-19 | Pieris Pharmaceuticals Gmbh | Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar simultaneamente as vias de sinalização, de coestimular células t, de induzir uma resposta de linfócitos e de induzir o aumento da citólise, composição farmacêutica e método para prevenir, melhorar ou tratar cânceres |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| EP4031166A1 (en) * | 2019-09-18 | 2022-07-27 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
| KR20230060546A (ko) | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| WO2024219897A1 (ko) | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| WO2024219894A1 (ko) | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5598894B2 (ja) * | 2006-03-03 | 2014-10-01 | 学校法人東京理科大学 | 生物活性を強化した抗体改変体 |
| CA2685698A1 (en) * | 2007-04-30 | 2008-11-13 | Centocor Ortho Biotech Inc. | Anti-tissue factor antibodies and compositions with enhanced effector function |
| BR112013019975A2 (pt) * | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
| MX2014001019A (es) * | 2011-07-27 | 2014-05-13 | Glaxo Group Ltd | Dominios variables singulares anti-vgf fusionados con dominios de fc. |
| WO2014138449A1 (en) * | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| US10858417B2 (en) * | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| IL286367B2 (en) * | 2014-05-02 | 2023-03-01 | Momenta Pharmaceuticals Inc | Compositions and methods relating to engineered fc constructs |
-
2018
- 2018-01-05 US US16/474,572 patent/US20200040084A1/en not_active Abandoned
- 2018-01-05 RU RU2019124709A patent/RU2019124709A/ru unknown
- 2018-01-05 EP EP18735797.5A patent/EP3565595A4/en not_active Withdrawn
- 2018-01-05 AU AU2018205272A patent/AU2018205272A1/en not_active Abandoned
- 2018-01-05 CA CA3049426A patent/CA3049426A1/en not_active Abandoned
- 2018-01-05 WO PCT/US2018/012689 patent/WO2018129397A1/en not_active Ceased
- 2018-01-05 JP JP2019537110A patent/JP2020514301A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514301A5 (enExample) | ||
| JP2020508655A5 (enExample) | ||
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| JP2018046872A5 (enExample) | ||
| JP2023052214A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021098732A5 (enExample) | ||
| JP2016505556A5 (enExample) | ||
| JP2020022482A5 (enExample) | ||
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| ES2533963T3 (es) | Composiciones farmacéuticas dirigidas a receptores Erb-B1 | |
| JP2017504577A5 (enExample) | ||
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| RU2013141956A (ru) | Антитело против ксф-1r | |
| JP2019534277A5 (enExample) | ||
| JP2018507188A5 (enExample) | ||
| RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| JP2010523592A5 (enExample) | ||
| JP2019528694A5 (enExample) | ||
| JPWO2020204152A5 (enExample) | ||
| JPWO2020160560A5 (enExample) | ||
| JP2016529213A5 (enExample) | ||
| JPWO2019166650A5 (enExample) |